Navigation Links
Clinical Renal Trails Do Not Have Sufficient Women Participants

New findings that are being presented during the American Society of Nephrology’s 38th Annual Meeting and Scientific Exposition in Philadelphia, Pennsylvania, say that women are not being adequately represented during medical trials // more specifically renal trials. Through analyses of the recently conducted renal trials showed this shortcoming.

It is theorized that this may be the reason why the US Food and Drug Administration (FDA) decided to withdraw many of these drugs from the market. It was found that over the last ten years, 8 out of 10 drugs that were ordered to be withdrawn had serious side effects in women. Dr. Julia Lewis of Vanderbilt University’s Division of Nephrology says that even with the above evidence women were underrepresented at clinical renal trials that were conducted to test the efficacy of certain drugs. She will speak at the symposium and say that pathogenesis of progressive renal disease and hypertension is dependent to some extent on sex hormones and ignoring these potentially harmful effects could adversely impact the health of women. Dr. Lewis is scheduled to speak at length on a topic titled “Gender Issues in Large Clinical Renal Trials,” during a symposium entitled, The Pathophysiology of Progressive Renal Disease and Hypertension: Importance of Gender and Ethnicity.

The meeting is being held from November 8-13 at the Pennsylvania Convention Center in Philadelphia, PA and focuses on distributing the latest research and clinical findings on kidney diseases among 12,000 nephrologists who assemble at the gathering
'"/>




Page: 1

Related medicine news :

1. Clinical trials need to be more frank
2. Physicians Lack Clinical Guidelines For Treating Elderly With Multiple Illnesses
3. The Growing Rise In Clinical Research Could Lead To A Compromise In Quality Of Research And Ethics
4. Clinical Comparisons Between ADHD Drugs Are Less
5. A Novel System For Clinical Banking Of Umbilical Cord Blood
6. Clinical Trials of New Drug Febuxostat Show Promise in Gout Treatment
7. Clinical Trials Of New Anti-Cancer Drug To Be Initiated In New Zealand
8. Green Tea Consumption Found To Improve Clinical Outcome In Cancer Patients
9. Cancer Clinical Research in India
10. New Generation Clinical Trials Could Save Time And Money, Improve Patient Care
11. Clinical Impact of Activity and Abdominal Pressure on Pelvic Floor Dysfunction Need to Be Further Analyzed
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/19/2017)... ... 2017 , ... ProBrand Glitch is a set of 30 glitch distortion logo reveals made exclusively ... any logo with a glitch reveal in just a few clicks of a mouse. Customizable ... of each preset. Use these presets to add a uniquely animated logo to any photos ...
(Date:2/18/2017)... VA (PRWEB) , ... February ... ... of Change for Devicemakers , Sponsored by Axendia, **FDAnews Free Webinar**, March ... , Are manufacturers looking to reduce their regulatory burden? Pay dividends in ...
(Date:2/18/2017)... ... 17, 2017 , ... CONTACT:, Glenn Vallecillos, MD, FACS, +1 ... Dr. Glenn Vallecillos experiments SculpSure, the hot, new, aesthetic, non-surgical procedure ... been centered around that idea that to achieve ones desired results a surgical ...
(Date:2/18/2017)... , ... February 18, 2017 , ... ... provides the latest information and contact points to easily connect elderly veterans of ... assisted living, and elder-care funding. It also conveys material on this year's increase ...
(Date:2/17/2017)... San Diego, CA (PRWEB) , ... February 17, ... ... new initiative—InvestUp—to focus on foundational and sustainable systems change designed to further positively ... Counties. , “The Board of Trustees has long considered it our duty to ...
Breaking Medicine News(10 mins):
(Date:2/20/2017)... South Africa , Feb. 20, 2017  There ... illness and non-communicable diseases (NCDs) across sub-Saharan Africa, which ... drugs. The growing incidence of more Western lifestyle diseases ... disease, in addition to infectious and parasitic illness, will ... with a business opportunity of $40.8 billion in ...
(Date:2/20/2017)... According to a new market research report "Pulmonary/ Respiratory Drug ... dose, Dry Powder, Nebulizer)), Canister (Plain, Coated), End User (Hospitals, Homecare), Applications ... to reach USD 52.37 Billion by 2021 from USD 36.10 Billion in ... Continue Reading ... ...
(Date:2/20/2017)... --  Alberty   Drugs , a leading ... has announced a significant shift in focus by concentrating ... servicing local Veteran Affairs Centers (VA) and other Federal ... need to secure cost effective treatments for their patients, ... their goods & services. "The opportunity to ...
Breaking Medicine Technology: